Filter posts

The Arrival of Actionable Personalized Medicine

The pace of implementation of next-generation sequencing (NGS) in a clinical context, which almost rivals …

New Cancer Treatments Seek to Give the Immune System Superpowers

Melanoma is scary. It is aggressive, spreads quickly to far-away organs with the stealth and …

JOBS Act Deconstructed: Regulation A

More than 40 biotech companies have gone public using provisions made available to emerging growth …

Fighting Blindness through Sound Investments in Research

Since 1971, the Foundation Fighting Blindness has raised more than half a billion dollars in …

Uniting To Accelerate Pediatric Medicine

Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use. A …

“Should the USPTO allow the patenting of living organisms?”

Most people associate patents with mechanical or electronic devices, new chemical substances, intricate machines or …

CTTI: Use of Central IRBs in Multi-Center Trials to Streamline Clinical Research

Multi-center clinical trials can provide high-quality, statistically-sound evidence to answer medical questions. Earlier this year, …

Prosensa's IPO and the Value of the BIO Investor Forum

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of …

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders …

Driving Innovation in Breast Cancer: Startup Challenge

The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for …